Panel Discussion: Overcoming the Phase II/III Roadblock: Reflecting on Lessons Learned to Drive Novel Mechanisms of Action Through Clinical Trials & Beyond
Time: 9:00 am
day: Day One AM
Details:
- What can we learn from successful pathways like Cobenfy to improve the success rate of phase II and III trials investigating new mechanisms?
- How can we mitigate the impact of high placebo response rates on clinical readouts?
- How did blinded data analytics feed into the results?
- What are the issues being encountered with patient selection in phase II and III? Are these new drugs being directed towards a responsive patient population?
- Are patients being stratified correctly and is a precision approach the key to seeing efficacy?
